Jan 14, 2021
News
Company completes four Focal One sales, including three bundled sales that combine Focal One® with Exact Imaging’s ExactVu micro ultrasound imaging solution. EDAP announces exclusive worldwide distribution rights to EXACT Imaging's Micro-Ultrasound Technologies Update on COVID-19 and the Potential Impact to Operations
Dec 9, 2020
Final US 2021 reimbursement rules for High Intensity Focused Ultrasound (HIFU)
U.S. Centers for Medicare and Medicaid Services (CMS) has issued its final rules establishing, for the first time, a Category 1 CPT code which facilitates reimbursement for the ablation of malignant prostate tissue with HIFU technology, effective January 1, 2021. Read more
Sep 3, 2020
First patients treated in phase 2 study of Focal One for the treatment of deep invasive endometriosis
the first two patients have been treated in the company’s Phase 2 clinical trial assessing Focal One® High Intensity Focused Ultrasound (HIFU) as a potential treatment for deep rectal endometriosis. A total of 38 women will be enrolled in the study and treated at five major hospitals and assessed over a six-month follow-up period. Read more
Aug 25, 2020
Approval received for phase II study evaluating HIFU for deep invasive endometriosis
EDAP TMS has received approval from French health authorities to initiate a Phase II multicenter clinical trial evaluating its Focal One® HIFU to treat deep rectal endometriosis. Read more
Aug 18, 2020
Two publications highlighting favorable HIFU focal therapy outcomes in journal of urology
Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015. Read more
Aug 18, 2020
Two publications highlighting favorable HIFU focal therapy outcomes in journal of urology
Studies conducted at the University of Southern California and University of Miami represent the first U.S. publications detailing successful partial-gland ablation using high intensity focused ultrasound therapy to treat prostate cancer patients since FDA cleared the technology in 2015. Read more
Jul 15, 2020
EDAP Announces Recent Focal One Sales Successes
May 12, 2020
EDAP announces exclusive worldwide distribution rights to EXACT Imaging's Micro-Ultrasound Technologies
Apr 23, 2020
B Riley FBR Initiates Research Coverage on EDAP TMS
Last week Andrew D’Silva of B Riley FBR launched research coverage on EDAP TMS with a buy-rating and price target at $5.50. Read more
Mar 17, 2020
EDAP TMS about COVID-19